Cannabinoid index · Altered & non-natural
Synthetic cannabinoids are lab-made or lab-altered compounds, from semi-synthetics such as HHC and THC-O to fully synthetic Spice/K2 chemicals, which are potent, unpredictable and linked to serious harm and deaths. Not every cannabinoid comes from the plant or the body. This index covers the “altered” cannabinoids in four groups: metabolites the body makes from THC and CBD (including the one drug tests look for), semi-synthetic cannabinoids converted in a lab from hemp (HHC, THC-O and the rest), approved and investigational pharmaceuticals, and the fully synthetic “Spice/K2” research chemicals.
| Compound | Formula | Intoxicating? | Known for / notes | Status |
|---|---|---|---|---|
| Human metabolites: what the body makes FROM cannabinoids | ||||
| 11-Hydroxy-THC (11-OH-THC) | C21H30O3 | Yes (active) | Active THC metabolite; prominent from edibles | |
| 11-Nor-9-carboxy-THC (THC-COOH) | C21H28O4 | No | The drug-test metabolite; inactive | |
| 7-Hydroxy-cannabidiol (7-OH-CBD) | C21H30O3 | No | Major active CBD metabolite | |
| 7-Carboxy-cannabidiol (7-COOH-CBD) | C21H28O4 | No | Terminal CBD metabolite | |
| Semi-synthetic / converted: consumer “novel” cannabinoids | ||||
| Hexahydrocannabinol (HHC) | C21H32O2 | Yes | Hydrogenated THC; more oxidation-stable | |
| THC-O-acetate (THC-O) | C23H32O3 | Yes (prodrug) | INHALATION HAZARD: heating can form ketene; do not vape | |
| HHC-O-acetate (HHC-O) | C23H34O3 | Yes | Acetylated HHC; same ketene caution as THC-O | |
| Hydrogenated CBD (H4CBD) | C21H34O2 | No | Hydrogenated CBD analog | |
| Hexahydrocannabiphorol (HHCP) | C23H36O2 | Yes (potent) | Hydrogenated 7-carbon analog | |
| Pharmaceutical: approved or investigational medicines | ||||
| Dronabinol | C21H30O2 | Yes | Synthetic Delta-9-THC (Marinol/Syndros); chemo nausea, AIDS anorexia | |
| Nabilone | C24H36O3 | Yes | Synthetic THC analog (Cesamet); chemo nausea | |
| Nabiximols | - | Yes | Sativex spray (1:1 THC:CBD); MS spasticity | |
| Rimonabant | C22H21Cl3N4O | No | Anti-obesity CB1 blocker; withdrawn for psychiatric effects | |
| Dexanabinol (HU-211) | C25H38O3 | No | Non-psychotropic enantiomer; NMDA antagonist | |
| Synthetic (Spice / K2 research chemicals): educational only | ||||
| JWH-018 | C24H23NO | Yes (potent) | First-generation ‘Spice’; potent CB1 full agonist, high harm risk | |
| JWH-073 | C23H21NO | Yes | Early Spice agonist | |
| CP-55,940 | C24H40O3 | Yes | Pfizer reference agonist; potency benchmark | |
| WIN-55,212-2 | C27H26N2O3 | Yes | Widely used lab agonist | |
| HU-210 | C25H38O3 | Yes (very potent) | ~100-800x THC potency; strictly research | |
| AM-2201 | C24H22FNO | Yes (potent) | Second-gen Spice; high harm risk | |
| 5F-MDMB-PINACA (5F-ADB) | C20H28FN3O3 | Yes (toxic) | Recent-gen; linked to deaths, severe toxicity | |
| MDMB-4en-PINACA | C21H29N3O3 | Yes (toxic) | Widely detected recent-gen agonist | |
“Forensic” status means the compound is characterised mainly through seizures and toxicology, not medical research. “Research tool” means it exists to study the receptors, not for human use.
Part of the NOIDS cannabinoids index · see also phytocannabinoids and endocannabinoids. Educational reference, not medical advice.
CB1 Full Agonism of Illicit Synthetic Cannabinoid Receptor Agonists Versus Partial Agonism of Phytocannabinoids
Illicit synthetic cannabinoid receptor agonists (SCRAs) such as JWH-018, 5F-ADB, and AMB-FUBINACA differ fundamentally in pharmacology and clinical toxicology from plant-derived delta-9-THC and semi-synthetic hydrogenated derivatives such as hexahydrocannabinol (HHC). As reviewed by Castaneto et al. (2014, Drug and Alcohol Dependence, PMID 27902569) and Tai & Fantegrossi (2017, Current Topics in Behavioral Neurosciences, PMID 27629237), whereas phytocannabinoid delta-9-THC acts as a partial agonist at central CB1 receptors with a ceiling effect on G-protein signaling, indole- and indazole-core SCRAs bind as high-affinity full CB1 agonists (`Ki` values often in the sub-nanomolar to low-nanomolar range) and generate active hydroxylated metabolites that retain full agonist efficacy, accounting for severe clinical toxicities including seizures, acute kidney injury, tachyarrhythmias, and fatalities documented in NIH StatPearls clinical toxicology reviews.